134 related articles for article (PubMed ID: 38490083)
1. A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood.
Manning B; Hayley AC; Catchlove S; Stough C; Downey LA
Eur Neuropsychopharmacol; 2024 May; 82():35-43. PubMed ID: 38490083
[TBL] [Abstract][Full Text] [Related]
2. Effect of CannEpil
Manning B; Hayley AC; Catchlove S; Shiferaw B; Stough C; Downey LA
J Psychopharmacol; 2023 May; 37(5):472-483. PubMed ID: 37129083
[TBL] [Abstract][Full Text] [Related]
3. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
[TBL] [Abstract][Full Text] [Related]
6. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
7. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
Gurgenci T; Hardy J; Huggett G; Foster K; Pelecanos A; Greer R; Philip J; Haywood A; Mendis R; Yates P; Good P
Trials; 2024 May; 25(1):293. PubMed ID: 38693590
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
[TBL] [Abstract][Full Text] [Related]
9. The acute effects of cannabis, with and without cannabidiol, on attentional bias to cannabis related cues: a randomised, double-blind, placebo-controlled, cross-over study.
Hall D; Lawn W; Ofori S; Trinci K; Borissova A; Mokrysz C; Petrilli K; Bloomfield MAP; Wall MB; Freeman TP; Curran HV
Psychopharmacology (Berl); 2024 Jun; 241(6):1125-1134. PubMed ID: 38416223
[TBL] [Abstract][Full Text] [Related]
10. Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.
Roser P; Gallinat J; Weinberg G; Juckel G; Gorynia I; Stadelmann AM
Eur Arch Psychiatry Clin Neurosci; 2009 Aug; 259(5):284-92. PubMed ID: 19224107
[TBL] [Abstract][Full Text] [Related]
11. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
13. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.
Fusar-Poli P; Crippa JA; Bhattacharyya S; Borgwardt SJ; Allen P; Martin-Santos R; Seal M; Surguladze SA; O'Carrol C; Atakan Z; Zuardi AW; McGuire PK
Arch Gen Psychiatry; 2009 Jan; 66(1):95-105. PubMed ID: 19124693
[TBL] [Abstract][Full Text] [Related]
14. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults.
Nicholson AN; Turner C; Stone BM; Robson PJ
J Clin Psychopharmacol; 2004 Jun; 24(3):305-13. PubMed ID: 15118485
[TBL] [Abstract][Full Text] [Related]
15. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.
Martin-Santos R; Crippa JA; Batalla A; Bhattacharyya S; Atakan Z; Borgwardt S; Allen P; Seal M; Langohr K; Farré M; Zuardi AW; McGuire PK
Curr Pharm Des; 2012; 18(32):4966-79. PubMed ID: 22716148
[TBL] [Abstract][Full Text] [Related]
16. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.
Spindle TR; Cone EJ; Goffi E; Weerts EM; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
Drug Alcohol Depend; 2020 Jun; 211():107937. PubMed ID: 32247649
[TBL] [Abstract][Full Text] [Related]
18. Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial.
Hunault CC; Böcker KB; Stellato RK; Kenemans JL; de Vries I; Meulenbelt J
Psychopharmacology (Berl); 2014 Dec; 231(24):4723-33. PubMed ID: 24879495
[TBL] [Abstract][Full Text] [Related]
19. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.
Lawn W; Trinci K; Mokrysz C; Borissova A; Ofori S; Petrilli K; Bloomfield M; Haniff ZR; Hall D; Fernandez-Vinson N; Wang S; Englund A; Chesney E; Wall MB; Freeman TP; Curran HV
Addiction; 2023 Jul; 118(7):1282-1294. PubMed ID: 36750134
[TBL] [Abstract][Full Text] [Related]
20. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
Haney M; Malcolm RJ; Babalonis S; Nuzzo PA; Cooper ZD; Bedi G; Gray KM; McRae-Clark A; Lofwall MR; Sparenborg S; Walsh SL
Neuropsychopharmacology; 2016 Jul; 41(8):1974-82. PubMed ID: 26708108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
